For example, obeticholic acid, which is a potent activator of FXR, improves hepatic steatosis, fibrosis, and portal hypertension in animal models of fatty liver disease [127,128,129] and the treatment of adult NASH patients resulted in improved histological features [110]. Here, NR1H4 is linked to fatty liver disease.